Objective: Analysis of palliative cryosurgery in rectal cancer patients.
Design: Descriptive.
Setting: Department of surgery, University Hospital Vrije Universiteit, Amsterdam, the Netherlands.
Methods: Ninety-three patients (age: 45-92 years) underwent palliative cryosurgery for primary rectal cancer. They were excluded from surgical resection because of old age, accompanying disease(s), inoperability and the presence of hematogenous metastases. The palliative effect of cryosurgery on local symptoms was classified as good, moderate or none. The duration of palliation was calculated in relation to survival as a palliative index: the number of months of (moderate or good) palliation divided by the number of months of survival from the start of the treatment, multiplied by 100%.
Results: In 58 patients (62%) there was complete relief of local symptoms with a palliative index of 87%. In 13 patients (14%) palliation was moderate and in 22 patients (24%) no palliation was achieved. The 50% survival duration in the 58 patients was 37 months. Especially symptoms of blood and/or mucous discharge could be easily alleviated. Good alleviation of local symptoms was associated with the extent of the primary tumour process. Palliative effect could be assessed after a few treatments. Patients with circular rectal tumours seldom had long term palliative effects of cryosurgery.
Conclusion: Cryosurgery for rectal cancer is a simple and safe treatment. It should be considered for alleviation of local symptoms in patients with rectal cancer who are unsuitable for radical surgery.
Download full-text PDF |
Source |
---|
Aims: With the recently validated tool for estimating chronic pain after colorectal cancer surgery, the aims of this study were to calculate the prevalence and to identify predictive risk factors for chronic pain after colorectal cancer treatment.
Method: Clinical data from colorectal cancer patients treated between 2001 and 2014 were obtained from the Danish Colorectal Cancer Group database. In 2016, all survivors were invited to participate in a national cross-sectional questionnaire study on long-term functional outcomes, including the chronic pain questionnaire.
Clin Transl Radiat Oncol
March 2025
University Medical Center Utrecht, Department of Radiation Oncology, Utrecht, the Netherlands.
Background And Purpose: This study assessed the treatment time of online adaptive (i.e. Adapt-to-Shape, ATS) and virtual couch shift (i.
View Article and Find Full Text PDFAME Case Rep
October 2024
Department of Oncology, Wenzhou Traditional Chinese Medicine Hospital of Zhejiang Chinese Medical University, Wenzhou, China.
Background: Hyperammonemic encephalopathy caused by high-dose infusion of 5-fluorouracil (5-FU) is a rare adverse reaction in rectal cancer patients with an incidence rate of 5.7%. Although the patient could be restored to normal after supportive treatments, the occurrence of this side effect was still inevitable.
View Article and Find Full Text PDFAME Case Rep
November 2024
Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Background: Mucinous adenocarcinoma is a rare type of colorectal cancer (CRC) associated with poor prognosis, particularly when it includes signet ring cell components. Furthermore, its rate of microsatellite instability-high (MSI-H) is significantly higher compared to non-mucinous adenocarcinoma. Immunotherapy has emerged as the standard treatment for MSI-H metastatic CRC (mCRC).
View Article and Find Full Text PDFFEBS Open Bio
January 2025
Clinical Measurement Sciences, Global Research & Development, EMD Serono, Billerica, MA, USA.
MAPK signaling activation is an important driver event in colorectal cancer (CRC) tumorigenesis that informs therapy selection, but detection by liquid biopsy can be challenging. We analyze real-world comprehensive genomic profiling (CGP) data to explore the landscape of alterations in BRAF or RAS in CRC patients (N = 51 982) and co-occurrence with other biomarkers. A pathogenic RAS or BRAF alteration was found in 63.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!